J&J reports positive phase 1/2 Covid-19 vaccine trial results Description video: CNBC’s Meg Tirrell reports that Johnson \u0026 Johnson has seen positive results from its Covid vaccine trial. With CNBC’s Melissa Lee and the Fast Money traders, Guy Adami, Tim […]
J&J reports positive phase 1/2 Covid-19 vaccine trial results
CNBC’s Meg Tirrell reports that Johnson \u0026 Johnson has seen positive results from its Covid vaccine trial. With CNBC’s Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Pete Najarian and Steve Grasso. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi \n\nJohnson \u0026 Johnson’s one-dose coronavirus vaccine is safe and appears to generate a promising immune response in both young and elderly volunteers, according to trial data published Wednesday in the New England Journal of Medicine.\n\nJ\u0026J scientists randomly assigned healthy adults between the ages of 18 and 55 and those 65 and older to receive a high or low dose of its vaccine — called Ad26.COV2.S — or a placebo. Some participants in the 18-to-55 age group were also selected to receive a second dose of the vaccine.\n\nMost of the volunteers produced detectable neutralizing antibodies, which researchers believe play an important role in defending cells against the virus, after 28 days, according to the trial data. By day 57, all volunteers had detectable antibodies, regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18-to-55 age group.\n\nThe most common side effects were fever, fatigue, headache, muscle aches and pain at the injection site, according to the trial data. Side effects were less common in the older age group, who received only one dose of the vaccine, as well as those who received a lower dose of the vaccine, according to the data.\n\nThe phase one and two clinical trial data shows a single shot of the vaccine “gives sustainable antibodies,” Dr. Paul Stoffels, chief scientific officer at J\u0026J, told CNBC’s Meg Tirrell in an interview. He added it gives the company “confidence” the vaccine will be highly effective against the virus.\n\nThe trial tested 805 volunteers. The company is expected to release results from its 45,000-person phase three trial later this month. J\u0026J is using the same technologies it used to develop its Ebola vaccine for its Covid-19 vaccine.\n\n» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision\n» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC\n» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic\n\nTurn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.\n\nThe News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast \n \nConnect with CNBC News Online\nGet the latest news: http://www.cnbc.com/\nFollow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC\nFollow CNBC News on Facebook: https://cnb.cx/LikeCNBC\nFollow CNBC News on Twitter: https://cnb.cx/FollowCNBC\nFollow CNBC News on Instagram: https://cnb.cx/InstagramCNBC\n\nhttps://www.cnbc.com/select/best-credit-cards/ \n\n#CNBC\n#CNBCTV
J&J announces imminent start of late-stage trials of its Covid-19 vaccine
Johnson & Johnson said it has recruited around 45,000 participants for its first late-stage trial of a Covid-19 vaccine candidate and expects interim data by the end of January..
However, the company is lagging behind rivals Pfizer and Moderna in the race for a vaccine to fight the Covid-19 pandemic, which has infected some 75 million people worldwide..
Study J&J titled Ensemble is run by Janssen’s division, the drug manufacturer said in a statement.
While seven countries have already authorized the emergency use of the vaccine from Pfizer and German firm BioNTech, a rival vaccine from Moderna is due to receive regulatory approval this week in the United States..
J&J also said she plans to apply for an emergency use authorization with the US Food and Drug Administration (FDA) in February if research data shows the vaccine is effective and safe for human health..
Earlier this month, the company announced a reduction in enrollment for the vaccine trial from its original plan of 60,000, as higher levels of Covid-19 infection amid a worsening pandemic should generate the data needed with fewer study participants..
In October, Ensemble’s trial was put on hold for more than a week after a patient developed «unexplained illness». The company later said it would resume testing after a special commission found no apparent the relationship between the cause of the patient’s illness and the drug administered.
Janssen said a separate clinical trial of the investigational Covid-19 vaccine is currently underway by Janssen to study the two-dose regimen..